Vascular Biogenics Ltd (VBLT)

[gr8db8]

Regarding Adam Feuerstein because his comments about VBLT have been brought up on this site ... I recently sold the last of my position on ARIA because it was acquired by Takeda for $5.2B.

The reason why I bring this guy's name up is because he's really a manipulator and says things to get clicks -- similar to click baits, similar to fake news. For years, he bashed ARIA (just like he has with VBLT), and his followers shorted the stock (often prior) to his misleading articles and tweets coming out.

If you look at the chart and the short interest on ARIA, there were many people who followed his advice ... many to their demise.

The next time you see something with his name attached to it, just remember that he likes to talk a lot .. sometimes he'll get some things right.

Here are some of the things he said about ARIA:

"FDA grants BTD to $ARIA ALK inhibitor AP26113. Hmmm. How can a me-too drug be considered breakthrough?"

FDA grants BTD to $ARIA ALK inhibitor AP26113. Hmmm. How can a me-too drug be considered breakthrough?

— Adam Feuerstein ✡️ (@adamfeuerstein) October 2, 2014

“Ariad sells a leukemia drug (Iclusig) with limited efficacy due to a worrisome safety profile. A competing leukemia drug is going generic soon,” wrote Feuerstein. “Ariad’s lead pipeline drug, brigatinib, is a me-too ALK inhibitor for a small subset of lung cancer patients that might be the third or fourth drug in its class to reach the market. "
https://www.biospace.com/News/why-ariad-could-be-worth-3-billion-to-a-big/373373